After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.
PFE - Pfizer Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$26.88
DETAILS
HIGH:
$30.00
LOW:
$25.00
MEDIAN:
$27.00
CONSENSUS:
$26.88
UPSIDE:
2.60%
Stock News
Pfizer: Q2 Strength Overshadows Obesity Setbacks
Pfizer shares edged higher after Q2 earnings, shrugging off criticism over the discontinuation of two obesity drug candidates, MET-224o and PF-07976016. PFE highlighted Metsera's rapid progress and plans to strategically deploy its remaining $6 billion-$7 billion toward bolt-on opportunities in oncology, IMIDs, and obesity. In Q2, sales of the tafamidis franchise were $1.76 billion, up 10% QoQ.
Boomers Should Buy These High-Yield Dividend August Bargains Hand-Over-Fist
Second-quarter earnings season shook loose some rare discounts on five high-yield dividend stocks that Wall Street analysts still rate as Buys, and income-focused investors may not get another shot at these prices.
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.
Pfizer Q2 Earnings Call Highlights
Pfizer NYSE: PFE reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% operationally.
Pfizer Inc. (PFE) Q2 2026 Earnings Call Transcript
Pfizer Inc. (PFE) Q2 2026 Earnings Call Transcript
PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer raises revenue outlook after quarterly earnings top estimates
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported adjusted earnings of $0.77 per share for the quarter, above the $0.68 expected by analysts.
Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 700 points on Tuesday.
Pfizer (PFE) Q2 Earnings and Revenues Top Estimates
Pfizer (PFE) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.
Pfizer Post Loss on Higher Revenue
Pfizer swung to a second-quarter loss but posted higher revenue, as market growth in its oncology business offset some declines in its Covid-19 products.
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing the stronger-than-expected performance of non-Covid products. The company is now expecting full-year revenue to total $60.5 billion to $62.5 billion, which compares to a previous outlook of $59.5 billion to $62.5 billion.
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
Pfizer beat Wall Street estimates for second-quarter profit on Tuesday, driven by strong demand for its blood thinner, Eliquis.
Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter, delivering on our financial commitments and adva.
Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday
With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
Pfizer raises revenue outlook after quarterly earnings top estimates
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue...
Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Pfizer Inc. (NYSE:PFE) will release its second quarter earnings report before the opening bell on Tuesday, Aug. 4.
Pfizer's Stock Has Been a Dud Over the Past 5 Years, but Is It Still Worth Buying for Its 6.9% Yield?
The stock's yield is more than six times the S&P 500 average.
Price Targets
Pfizer downgraded to Hold from Buy at HSBC
$28.00
(was $24.32)
HSBC
UBS Reiterates Neutral Rating on Pfizer (PFE)
$27.00
(was $26.34)
Michael Yee
·
UBS
Pfizer price target raised to $26 from $25 at Wolfe Research
$26.00
(was $25.96)
Alexandria Hammond
·
Wolfe Research
Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive'
$27.00
(was $27.05)
Terence Flynn
·
Morgan Stanley
BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data
$30.00
(was $26.48)
Evan David Seigerman
·
BMO Capital
RBC Capital Starts Pfizer (PFE) at Underperform
$25.00
(was $27.14)
Trung Huynh
·
RBC Capital
Pfizer initiated with an Underweight at Barclays
$25.00
(was $26.86)
Emily Field
·
Barclays
Pfizer downgraded to Neutral from Outperform at Daiwa
$27.00
(was $27.73)
Narumi Nakagiri
·
Daiwa
Pfizer price target raised to $27 from $24 at Cantor Fitzgerald
$27.00
(was $25.88)
Cantor Fitzgerald
Pfizer assumed with a Neutral at UBS
$25.00
(was $25.43)
UBS
Pfizer (PFE) PT Lowered to $24 at Wolfe Research
$24.00
(was $25.53)
Alexandria Hammond
·
Wolfe Research
Pfizer price target lowered to $28 from $32 at Morgan Stanley
$28.00
(was $25.89)
Morgan Stanley
Pfizer price target raised to $29 from $28 at HSBC
$29.00
(was $25.33)
Rajesh Kumar
·
HSBC
Pfizer price target raised to $35 from $33 at Guggenheim
$35.00
(was $25.17)
Guggenheim
Goldman Sachs on Pfizer (PFE): 'Challenging Crosscurrents As Focus Shifts To 2026 Guidance Next Month'
$26.00
(was $24.23)
Asad Haider
·
Goldman Sachs
Bernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE), 'a sore loss for Pfizer' if Novo are successful in bid for Metsera
$30.00
(was $24.45)
Courtney Breen
·
Bernstein
Pfizer price target lowered to $32 from $33 at Morgan Stanley
$32.00
(was $25.24)
Morgan Stanley
Pfizer drug pricing deal 'mostly performative,' says BofA
$28.00
(was $27.16)
Tim Anderson
·
UBS
Pfizer initiated with a Neutral at Cantor Fitzgerald
$24.00
(was $22.53)
Carter Gould
·
Cantor Fitzgerald
Pfizer price target lowered to $32 from $36 at Truist
$32.00
(was $25.89)
Robyn Karnauskas
·
Truist Financial